GlassScriptPhysician profile
Abigail Adams Eckard
NPI 1508542796
$566.23
in general payments reported to CMS, 2019-2025
15 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $284 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $109.77 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $74.60 | 2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $53.83 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.91 | 2023-2024 | Jardiance |
| Pfizer INC. | $50.95 | 2025 | |
| Organon LLC | $40.70 | 2024-2025 | Nexplanon |
| Exact Sciences Corporation | $38.31 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $22.86 | 2023 | Nexletol |
| Sumitomo Pharma America, INC. | $20.62 | 2023 | Gemtesa |
| Tandem Diabetes Care, INC. | $20.49 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $17.98 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $17.73 | 2024 | Farxiga |
| Abbvie INC. | $16.40 | 2023 | |
| Astellas Pharma US INC | $16.21 | 2024 | Veozah |
| Amgen INC. | $13.87 | 2023 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Eckard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.